Russell Investments Group Ltd. Grows Stock Holdings in Stryker Corporation $SYK

Posted by Brenda Bartman on Aug 17th, 2026

Russell Investments Group Ltd. boosted its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 54.2% during the second quarter, Holdings Channel reports. The firm owned 420,962 shares of the medical technology company’s stock after purchasing an additional 147,977 shares during the quarter. Russell Investments Group Ltd.’s holdings in Stryker were worth $133,576,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in SYK. Sankala Group LLC bought a new position in shares of Stryker during the 4th quarter valued at $26,000. Godfrey Financial Associates Inc. bought a new position in Stryker in the fourth quarter valued at about $26,000. United Financial Planning Group LLC purchased a new position in Stryker in the third quarter worth about $27,000. Atlas Capital Advisors Inc. bought a new stake in shares of Stryker during the 4th quarter valued at about $27,000. Finally, DJE Kapital AG purchased a new stake in shares of Stryker during the 4th quarter valued at about $28,000. Institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on SYK shares. Truist Financial boosted their target price on shares of Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Wolfe Research cut Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday. Wells Fargo & Company cut their price target on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Finally, Citizens Jmp decreased their price objective on Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Read Our Latest Report on SYK

Stryker Stock Down 0.1%

Shares of SYK stock opened at $338.80 on Monday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The company’s fifty day moving average price is $324.61 and its 200-day moving average price is $333.40. The company has a market capitalization of $129.95 billion, a price-to-earnings ratio of 35.11, a PEG ratio of 2.16 and a beta of 0.76.

Stryker (NYSE:SYK – Get Free Report) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the prior year, the firm posted $3.13 EPS. Stryker’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts expect that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s dividend payout ratio is 36.48%.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.60% of the company’s stock.

Stryker Company Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.